Keyword: University of California Berkeley
The Broad Institute just lost the latest skirmish over ownership of the intellectual property surrounding the gene-editing CRISPR/Cas9 technology.
A new form of CRISPR/Cas9 activates specific genes without making breaks in the DNA, which can reduce harmful side effects.
The deal gives Excision the exclusive right to use the recently discovered Cas9 alternatives to treat infectious diseases.
UC Berkeley scientists are using a new CRISPR delivery system to more safely correct the mutated dystrophin gene in mouse models of DMD.
Novartis and UC Berkeley have formed a pact to unlock difficult drug targets and boost development of new meds in infectious diseases and cancer.
A "blunted" version of CRISPR can be used to identify gene regulators in the genome and help unravel autoimmune disease.
Researchers have created a surgical glue, inspired by mussels, that may make fetal surgery more feasible.
Anti-CRISPR proteins may be the key to preventing harmful side effects from off-target editing.
Celgene has landed an option on four natural killer cell-based blood cancer therapeutics in a deal with Dragonfly Therapeutics.
Shares in Editas Medicine rose 30% after the U.S. patent office sided with the Broad Institute in the legal tussle over CRISPR gene editing.